secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001837607-25-000025
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON CEO Marc Forth resigns; Chairman Jost Fischer named interim CEO
--------------------------------------------------------------------

- Marc Forth steps down as President and CEO effective April 4, 2025, to pursue another opportunity.
- Forth remains on the board; departure is not due to any disagreement with AEON.
- Chairman Jost Fischer appointed Interim CEO; board actively seeking permanent replacement.
- AEON expects current cash to fund through Biosimilar BPD Type 2a meeting with FDA in H2 2025.
- AEON is a clinical-stage biopharma developing botulinum toxin complex ABP-450 as a BOTOX biosimilar.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000025/0001837607-25-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000025/aeon-20250324x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-25-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer